Axsome Therapeutics
Open
$254.53
Prev. Close
$255.29
High
$255.43
Low
$254.53
Market Snapshot
$13.05B
-69.3
-5.99
$385.69M
925
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. The company is headquartered in New York City, New York and currently employs 925 full-time employees. The company went IPO on 2015-11-19. The firm focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. The company is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Axsome Therapeutics settled SUNOSI patent litigation, opening pathways for generics by 2040, which is expected to enhance the company's growth prospects significantly.
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. The company is headquartered in New York City, New York and currently employs 925 full-time employees. The company went IPO on 2015-11-19. The firm focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. The company is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Recently from Cashu
Axsome Therapeutics Settles SUNOSI Litigation, Securing Market Exclusivity Until 2040
Axsome Therapeutics, a biopharmaceutical company focused on central nervous system (CNS) disorders, recently resolves significant litigation related to its wakefulness drug SUNOSI. This settlement per…
Axsome Therapeutics Prepares for Auvelity Launch, Targeting Alzheimer's Agitation Market
Axsome Therapeutics (Ticker: AXSM) is making strategic advancements in its product portfolio, particularly with the anticipated launch of Auvelity, a treatment aimed at agitation in Alzheimer's diseas…
Axsome Therapeutics Receives FDA Approval for AUVELITY: A Breakthrough Alzheimer’s Agitation Treatment
Axsome Therapeutics (Ticker: AXSM) has achieved a significant milestone by receiving U.S. FDA approval for AUVELITY, which is now recognized as the first non-antipsychotic medication specifically targ…
Helus Pharma's Psychedelic Breakthroughs Signal New Era in Mental Health Treatments
Helus Pharma's Promising Psychedelic Therapy: A Step Forward in Mental Health Treatments Helus Pharma, a clinical-stage pharmaceutical company, achieves a groundbreaking milestone with its positive ou…